Lung cancer is the leading cause of cancer-related deaths in the US and disproportionally affects Veterans. Advances in non-small-cell lung cancer over the past decade have resulted in new molecularly targeted therapies with minimal toxic effects and dramatic clinical benefits. However, despite these progresses, overall five-year survival remains at approximately 16%, partly due to low responsive rate to targeted therapy, development of acquired resistance, difficulty of targeting certain proteins such as mutant K-RAS, and a large subset with undefined genetic alterations. Therefore, new molecular targets are needed for lung cancer subtypes that are currently refractory to available treatments. EphA2 is such a promising target. EphA2 is overexpressed in NSCLC, and high levels of EphA2 correlate with smoking, brain metastasis, disease relapse, and poor patient survival. A gain-of- function EphA2 mutation has also been identified in tumor specimens, suggesting an oncogenic role of EphA2 in lung cancer. Indeed, we discovered that knockdown of EphA2 in a large numbers of human lung cancer cell lines inhibited tumor cell viability, most dramatically affecting those bearing mutant K-RAS or carrying EGFR mutation that developed acquired resistance to tyrosine kinase inhibitors (TKI). To support this notion, an EphA2 small molecule kinase inhibitor suppressed cell viability in vitro and induced tumor regression in K-RAS mutant human lung cancer xenografts. Based on these preliminary data, the overall goal of this VA Merit renewal is to determine the efficacy of targeting EphA2 in lung cancer subtypes that are refractory to current targeted treatment, to elucidate molecular basis for EphA2 function in tumor, and to test small molecule EphA2 kinase inhibitors for cancer therapeutics. We will first to investigate the effects of EphA2 deficiency on lung cancer development and progression in vivo in transgenic K-RAS G12D and TKI-resistant EGFR L858R+T790M lung cancer models. To elucidate EphA2 receptor downstream signaling, we will focus on the JNK/c-Jun pathway in regulating tumor cell viability and tumor stem-like cell function. Finally, we will test the efficacy of selective small molecule inhibitors of EphA2 receptor. Success of this project will not only generate novel insights into the molecular basis whereby EphA2 RTK regulates tumor cell viability, but also provide novel EphA2- selective inhibitors for treatment of lung cancer subtypes that are refractory to current targeted therapies, such as K-RAS mutant and drug-resistant EGFR mutant lung cancers.
Public Health Relevance Statement Lung cancer is a devastating disease that disproportionally affects Veterans. Although several molecularly targeted therapies have been developed, only small percentage of patients responds to such therapies and drug resistance develops following prolonged treatment. In addition, it is often difficult to develop treatment of certain categories f lung cancer (such as those bearing K-RAS mutation). We recently discovered that a cell-surface molecule, called EphA2, is required for tumor cell viability in lung cancers that are refractory to available targeted treatments. Our overall goal of this project is to determine the efficacy of targeting EphA2 in lung cancers, to elucidate how EphA2 functions in tumor, and to test new drugs targeting EphA2 in subtypes of lung cancer that are currently refractory to targeted therapies.
|Kim, L C; Cook, R S; Chen, J (2017) mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene 36:2191-2201|
|Edwards, Deanna N; Ngwa, Verra M; Wang, Shan et al. (2017) The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ. Sci Signal 10:|
|Song, W; Hwang, Y; Youngblood, V M et al. (2017) Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers. Oncogene 36:5620-5630|
|Youngblood, Victoria M; Kim, Laura C; Edwards, Deanna N et al. (2016) The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer. Cancer Res 76:1825-36|
|Shiuan, Eileen; Chen, Jin (2016) Eph Receptor Tyrosine Kinases in Tumor Immunity. Cancer Res 76:6452-6457|
|Amato, Katherine R; Wang, Shan; Tan, Li et al. (2016) EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Res 76:305-18|
|Wang, Shan; Amato, Katherine R; Song, Wenqiang et al. (2015) Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways. Mol Cell Biol 35:1299-313|
|Youngblood, Victoria; Wang, Shan; Song, Wenqiang et al. (2015) Elevated Slit2 Activity Impairs VEGF-Induced Angiogenesis and Tumor Neovascularization in EphA2-Deficient Endothelium. Mol Cancer Res 13:524-37|
|Chen, Jin; Song, Wenqiang; Amato, Katherine (2015) Eph receptor tyrosine kinases in cancer stem cells. Cytokine Growth Factor Rev 26:1-6|